Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register
暂无分享,去创建一个
C. Porsbjerg | L. Rasmussen | O. Hilberg | C. Ulrik | K. Assing | S. Hansen | A. von Bülow | C. Johnsen | T. Ingebrigtsen | K. Håkansson | J. Schmid | Marianne Baastrup Soendergaard | A. Bjerrum | Sofie Lock-Johansson | M. B. Soendergaard
[1] T. Hirano,et al. Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic Approach , 2021, Journal of asthma and allergy.
[2] J. Upham,et al. Defining a severe asthma super-responder: findings from a Delphi process. , 2021, The journal of allergy and clinical immunology. In practice.
[3] J. A. Gullón Blanco,et al. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study , 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.
[4] T. Skjold,et al. Oral corticosteroid sparing effects of anti-IL5/ anti-IL5 receptor treatment after 2 years of treatment. , 2020, Respiratory medicine.
[5] C. Porsbjerg,et al. The Danish severe asthma register: an electronic platform for severe asthma management and research , 2020, European clinical respiratory journal.
[6] E. Bel,et al. Long-term therapy response to anti-interleukin-5 biologics in severe asthma - a real-life evaluation. , 2020, The journal of allergy and clinical immunology. In practice.
[7] M. Idzko,et al. Effectiveness of Mepolizumab Therapy in Patients with Severe Eosinophilic Asthma: Austrian real-life data. , 2020, Pulmonary pharmacology & therapeutics.
[8] A. Douiri,et al. Real World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. , 2020, Chest.
[9] R. Terracciano,et al. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[10] K. Samitas,et al. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis , 2020, International Archives of Allergy and Immunology.
[11] G. Canonica,et al. Minimal clinically important difference for asthma endpoints: an expert consensus report , 2020, European Respiratory Review.
[12] L. Boulet,et al. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena , 2020, European Respiratory Journal.
[13] M. Mäkelä,et al. A comparison of biologicals in the treatment of adults with severe asthma – real-life experiences , 2020, Asthma Research and Practice.
[14] E. Heffler,et al. Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[15] J. Kavanagh,et al. Real-World Effectiveness and the Characteristics of a 'Super-Responder' to Mepolizumab in Severe Eosinophilic Asthma. , 2020, Chest.
[16] M. Humbert,et al. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme , 2020, European Respiratory Journal.
[17] R. Louis,et al. Real‐world experience with mepolizumab: Does it deliver what it has promised? , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[18] C. Jenkins,et al. Mepolizumab effectiveness and identification of super-responders in severe asthma , 2020, European Respiratory Journal.
[19] G. Braunstahl,et al. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety , 2020, The Journal of asthma : official journal of the Association for the Care of Asthma.
[20] John Macsharry,et al. The effectiveness of Reslizumab in severe asthma treatment: a real-world experience , 2019, Respiratory Research.
[21] F. Albers,et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. , 2019, Respiratory medicine.
[22] Ashokakumar M. Patel,et al. NEWER BIOLOGICAL AGENTS IN THE TREATMENT OF SEVERE ASTHMA: REAL WORLD RESULTS FROM A TERTIARY REFERRAL CENTER , 2019, Chest.
[23] M. Cabana,et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline , 2019, European Respiratory Journal.
[24] B. Pertzov,et al. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma , 2019, The Journal of asthma : official journal of the Association for the Care of Asthma.
[25] G. Canonica,et al. One year of mepolizumab. Efficacy and safety in real-life in Italy. , 2019, Pulmonary pharmacology & therapeutics.
[26] G. Canonica,et al. The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials , 2018, The World Allergy Organization journal.
[27] R. Terracciano,et al. Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study. , 2018, Pulmonary pharmacology & therapeutics.
[28] T. Welte,et al. Anti-IL-5 therapy in patients with severe eosinophilic asthma – clinical efficacy and possible criteria for treatment response , 2018, BMC Pulmonary Medicine.
[29] D. Lúdvíksdóttir,et al. Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults , 2018, European clinical respiratory journal.
[30] K. Rabe,et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.
[31] E. Bleecker,et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.
[32] P. Chanez,et al. External Validity of Randomized Controlled Trials in Severe Asthma. , 2015, American journal of respiratory and critical care medicine.
[33] E. Bateman,et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.
[34] A. Zwinderman,et al. The prevalence of severe refractory asthma. , 2015, The Journal of allergy and clinical immunology.
[35] C. Porsbjerg,et al. The prevalence of severe asthma and low asthma control among Danish adults. , 2014, The journal of allergy and clinical immunology. In practice.
[36] Ian D Pavord,et al. Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.
[37] I. Pavord,et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.
[38] Ian D Pavord,et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.
[39] Parameswaran Nair,et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.
[40] E. Bleecker,et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.
[41] Anand A. Dalal,et al. Utilization and Costs of Severe Uncontrolled Asthma in a Managed-Care Setting. , 2016, The journal of allergy and clinical immunology. In practice.
[42] S. Willsie. Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma , 2010 .
[43] G. Crompton,et al. Management of Severe Asthma , 1998 .
[44] W. Busse,et al. The Relationship of Asthma Biologics to Remission for Asthma , 2022, The Journal of Allergy and Clinical Immunology: In Practice.